Business news for the stock market
Leverkusen, Germany (pta022/14.12.2021/17:15) - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announces the results of the election to the new Supervisory Board at the Annual General Meeting on December 14, 2021. The shareholders present represented about 64% of the registered share capital.
As reported by the company on November 19, 2021, agreement was reached on the Supervisory Board candidates for election on December 14, 2021, as part of the mediation process between the Deutsche Balaton Group and the then incumbent Supervisory Board of Biofrontera AG.
The five new members, Dr. Heikki Lanckriet, Dr. Helge Lubenow, Karlheimz Schmelig, Dr. Jörgen Tielmann and Wilhelm K. T. Zours, were elected to the Supervisory Board by the Company's Annual General Meeting on December 14, 2021, replacing the departing members Dr. Ulrich Granzer, Jürgen Baumann, Dr. John Borer, Reinhard Eyring and Kevin Weber. Prof. Dr. Franca Ruhwedel was re-elected to the Supervisory Board.
At its constituting meeting on December 14, 2021, the Supervisory Board elected Wilhelm K. T. Zours as its Chairman and Dr. Jörgen Tielmann as Vice Chairman of the Supervisory Board.
The Company made use of the option provided by the German legislator in view of the coronavirus pandemic to conduct the ordinary AGM as a virtual meeting without the physical presence of shareholders or their proxies. Via a password-protected online platform, registered shareholders could, among other things, visually and audibly follow the entire Annual General Meeting, exercise their voting rights and submit questions until two days prior to the AGM.
Further information on the Annual General Meeting including the detailed voting results and the Management Board presentation can be found at: https://www.biofrontera.com/en/annual-general-meeting.html
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq